Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 40.75
Bid: 40.00
Ask: 41.50
Change: 0.25 (0.62%)
Spread: 1.50 (3.75%)
Open: 40.20
High: 40.75
Low: 40.20
Prev. Close: 40.50
VLG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of General Meeting and Open Offer

8 Dec 2020 12:00

RNS Number : 9415H
Venture Life Group PLC
08 December 2020
 

THIS ANNOUNCEMENT, INLCUDING THE INFORMATION CONTAINED IN IT, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION, DISTRIBUTION OR FORWARDING, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.

 

FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION.

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION.

 

LEI: 213800S8CZUPLAB2KC70

 

 

8 December 2020

 

Venture Life Group plc

("Venture Life" or the "Company")

 

Results of Placing and Open Offer

and Result of General Meeting

 

On 20 November 2020, Venture Life announced a conditional Placing to raise £34 million and an Open Offer to raise up to an additional £2.0 million.

 

The Company is pleased to announce that at its General Meeting held today all of the resolutions, as set out in the Circular dated 20 November 2020, were duly passed.

 

The Company is also pleased to announce the results of the Open Offer, which closed for acceptances at 11:00 a.m. on 7 December 2020 and was oversubscribed. Valid acceptances have been received in respect of 3,614,034 Open Offer Shares, representing 159.14 per cent. of the Open Offer Shares available under the Open Offer. In accordance with the terms and conditions of the Open Offer all applications made pursuant to the Open Offer (other than Excess Shares applied for under the Excess Application Facility) have been met in full and a scaling back exercise has been undertaken in respect of applications for Excess Shares. The Company has therefore raised gross proceeds of approximately £2.04 million through the Open Offer.

 

As set out in the Circular dated 20 November 2020, certain Directors of the Company indicated their intention to sell an aggregate of 8,173,343 Sale Shares at the Offer Price. The Sale is conditional, inter alia, on Admission. As further detailed in the Circular, and also in the Company's announcement on 24 November 2020 (RNS No. 2482G), the Sales Shares will include 1,735,774 Ordinary Shares that are to be issued and allotted to Jerry Randall and Sharon Daly (née Collins) upon the exercise, by both of them, of 867,887 EMI Options. Following exercise of the EMI Options and the sale of the Sale Shares, the Sellers (and their families/pension plans) will retain the following interests:

 

Interests prior to the Placing and Open Offer

Interests at Admission

No. of Ordinary Shares(1)

Percentage of issued share capital(1)

No. of Ordinary Shares(1)

Percentage of issued share capital(1)

Jerry Randall

3,769,729

4.5%

1,884,865(2)

1.5%(2)

Sharon Daly (née Collins)

2,019,953

2.4%

1,009,977(3)

0.8%(3)

Gianluca Braguti

7,085,459(4)

8.4%(4)

3,542,730(5)

2.8%(5)

 

Notes:

(1) Excluding share options. The legal title of all Ordinary Shares for which the Sellers hold the beneficial interest is held by Vestra Nominees Limited.

(2) Having exercised 867,887 EMI Options for Ordinary Shares which will all be sold in the Sale. On Admission, Jerry Randall is expected to hold the beneficial interests to 653,013 Ordinary Shares and his wife, Mrs A Randall, is expected to hold the beneficial interests to 1,231,852 Ordinary Shares.

(3) Having exercised 867,887 EMI Options for Ordinary Shares which will all be sold in the Sale. On Admission, Sharon Daly is expected to hold the beneficial interests to 591,197 Ordinary Shares and her husband, Mr C Daly, is expected to hold the beneficial interests to 418,779 Ordinary Shares

(4) Including 2,300,000 Ordinary Shares to which his wife and his adult children hold the beneficial interest. Gianluca Braguti retains control of the voting rights for these Ordinary Shares whilst he remains a Director of the Company.

(5) Including 1,150,000 Ordinary Shares to which his wife and his adult children hold the beneficial interest. Gianluca Braguti will retain control of the voting rights for these Ordinary Shares whilst he remains a Director.

 

 

Application has been made for a total of 41,784,524 new Ordinary Shares, to be issued pursuant to the Placing, Open Offer and as a result of the exercise of the EMI Options, to be admitted to trading on AIM. It is expected that Admission and dealings in the 41,784,524 new Ordinary Shares will commence at 8.00 a.m. on 9 December 2020. Following Admission, the Enlarged Share Capital of the Company will consist of 125,810,530 Ordinary Shares. Therefore, the total number of voting rights in the Company is 125,810,530 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in the Company, or there is a change to their interest in the Company.

 

 

This announcement should be read in conjunction with the full text of the Circular posted to Shareholders on 20 November 2020, copies of which are available on the Company's website www.venture-life.com. The same definitions apply throughout this announcement as are applied in the Circular

 

 

Venture Life Group PLC

+44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

 

Cenkos Securities plc (Nomad and Joint Broker)

 

+44 (0) 20 7397 8900

Stephen Keys / Camilla Hume (Corporate Finance)

Russell Kerr / Michael Johnson (Sales)

 

N+1 Singer (Joint Broker)

 

+44 (0) 20 7496 3000

Shaun Dobson / Carlo Spingardi

 

 

Important Notices

 

No action has been taken by the Cenkos Securities plc ("Cenkos") or any of its affiliates, or any person acting on its or their behalf that would permit an offer of the New Ordinary Shares or possession or distribution of this announcement or any other offering or publicity material relating to such New Ordinary Shares in any jurisdiction where action for that purpose is required. Persons into whose possession this announcement comes are required by the Company and Cenkos to inform themselves about, and to observe, such restrictions.

 

No prospectus, offering memorandum, offering document or admission document has been or will be made available in connection with the matters contained in this announcement and no such prospectus is required (in accordance with the Prospectus Regulation) to be published. Persons needing advice should consult a qualified independent legal adviser, business adviser, financial adviser or tax adviser for legal, financial, business or tax advice.

 

THIS ANNOUNCEMENT, INCLUDING THE INFORMATION CONTAINED IN IT, IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE, FORWARDING OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA (COLLECTIVELY, THE "UNITED STATES"), AUSTRALIA, NEW ZEALAND, CANADA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL. FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION. THIS ANNOUNCEMENT HAS NOT BEEN APPROVED BY THE LONDON STOCK EXCHANGE, NOR IS IT INTENDED THAT IT WILL BE SO APPROVED.

 

This announcement or any part of it does not constitute or form part of any offer to issue or sell, or the solicitation of an offer to acquire, purchase or subscribe for, any securities in the United States, Canada, Australia, New Zealand, the Republic of South Africa, Japan or any other jurisdiction in which the same would be unlawful. No public offering of the Placing Shares is being made in any such jurisdiction.

 

The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or with any securities regulatory authority of any State or other jurisdiction of the United States, and may not be offered, sold or transferred directly or indirectly in or into the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of any State or any other jurisdiction of the United States. Accordingly, the Placing Shares are being offered and sold by the Company only outside the United States in "offshore transactions" (as such terms are defined in Regulation S under the Securities Act ("Regulation S")) pursuant to Regulation S under the Securities Act and otherwise in accordance with applicable laws. No public offering of securities is being made in the United States.

 

Certain statements contained in this announcement constitute "forward-looking statements" with respect to the financial condition, results of operations and businesses and plans of the Company and its subsidiaries (the "Group"). Words such as "believes", "anticipates", "estimates", "expects", "intends", "plans", "aims", "potential", "will", "would", "could", "considered", "likely", "estimate" and variations of these words and similar future or conditional expressions, are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. These statements and forecasts involve risk and uncertainty because they relate to events and depend upon future circumstances that have not occurred. There are a number of factors that could cause actual results or developments to differ materially from those expressed or implied by these forward-looking statements and forecasts. As a result, the Group's actual financial condition, results of operations and business and plans may differ materially from the plans, goals and expectations expressed or implied by these forward-looking statements. No representation or warranty is made as to the achievement or reasonableness of, and no reliance should be placed on, such forward-looking statements. No statement in this announcement is intended to be, nor may it be construed as, a profit forecast or be relied upon as a guide to future performance. The forward-looking statements contained in this announcement speak only as of the date of this announcement. The Company, its directors, Cenkos, their respective affiliates and any person acting on its or their behalf each expressly disclaim any obligation or undertaking to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, unless required to do so by applicable law or regulation, the AIM Rules or the rules of the London Stock Exchange.

 

Cenkos Securities plc is authorised and regulated in the United Kingdom by the FCA. Cenkos is acting exclusively for the Company and no one else in connection with the Placing and will not regard any other person (whether or not a recipient on this announcement) as its client in relation to the Placing or any other matter referred to in this announcement and will not be responsible to anyone (including any Placees) other than the Company for providing the protections afforded to its clients or for providing advice to any other person in relation to the Placing or any other matters referred to in this announcement.

 

This announcement has been issued by and is the sole responsibility of the Company. No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by Cenkos or by any of its affiliates or any person acting on its or their behalf as to, or in relation to, the accuracy or completeness of this announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefore is expressly disclaimed.

 

Any indication in this announcement of the price at which ordinary shares have been bought or sold in the past cannot be relied upon as a guide to future performance. The price of shares and any income expected from them may go down as well as up and investors may not get back the full amount invested upon disposal of the shares. Past performance is no guide to future performance. The contents of this announcement are not to be construed as legal, business, financial or tax advice. Each investor or prospective investor should consult his, her or its own legal adviser, business adviser, financial adviser or tax adviser for legal, financial, business or tax advice.

 

Persons (including, without limitation, nominees and trustees) who have a contractual or other legal obligation to forward a copy of this announcement should seek appropriate advice before taking any action.

 

Neither the content of the Company's website (or any other website) nor the content of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into or forms part of this announcement.

 

This announcement has been prepared for the purposes of complying with applicable law and regulation in the United Kingdom and the information disclosed may not be the same as that which would have been disclosed if this announcement had been prepared in accordance with the laws and regulations of any jurisdiction outside the United Kingdom.

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUPGBCPUPUGGR
Date   Source Headline
19th Apr 20247:00 amRNSRCF in Place and New Partner in the USA
9th Apr 20247:00 amRNSFinal Results for year ended 31 December 2023
4th Apr 20247:00 amRNSNotice of Results and Investor Presentation
19th Feb 20245:18 pmRNSHolding(s) in Company
6th Feb 202410:48 amRNSHolding(s) in Company
1st Feb 20247:00 amRNSTrading Update
20th Dec 20232:00 pmRNSHolding(s) in Company
28th Nov 202312:28 pmRNSHolding(s) in Company
22nd Nov 20234:05 pmRNSHolding(s) in Company
14th Nov 20237:00 amRNSChange of Nominated Adviser and Broker
31st Oct 20233:11 pmRNSHolding(s) in Company
17th Oct 20231:54 pmRNSHolding(s) in Company
25th Sep 20237:01 amRNSDirector/PDMR Shareholding
25th Sep 20237:00 amRNSHalf-year Report
5th Sep 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSTrading Statement
5th Jul 20237:00 amRNSPDMR Shareholdings – Grant of Awards
26th Jun 20234:48 pmRNSDirector/PDMR Shareholding
25th May 20231:54 pmRNSDirector Dealings
22nd May 20233:01 pmRNSResults of AGM
22nd May 20237:00 amRNSAGM Statement
19th May 20237:00 amRNSBoard Change
9th May 20237:00 amRNSNotice of Capital Markets Event
28th Apr 202310:05 amRNSAnnual Report and Notice of AGM
5th Apr 20231:53 pmRNSDirector/PDMR Shareholding
4th Apr 20237:00 amRNSFinal Results for year ended 31 December 2022
31st Mar 20237:00 amRNSInvestor Presentation
13th Mar 20237:00 amRNSUpdate re Revolving Credit Facility
10th Mar 20232:05 pmRNSSecond Price Monitoring Extn
10th Mar 20232:00 pmRNSPrice Monitoring Extension
31st Jan 20237:00 amRNSTrading Statement
9th Jan 20237:00 amRNSLicensing and distribution agreements
1st Dec 20224:41 pmRNSSecond Price Monitoring Extn
1st Dec 20224:37 pmRNSPrice Monitoring Extension
1st Dec 20227:00 amRNSAcquisition and trading update
10th Oct 20227:00 amRNSDirectorate Changes
23rd Sep 202211:08 amRNSInvestor Presentation
22nd Sep 20227:00 amRNSHalf-year Report
25th Jul 202212:00 pmRNSDirector/PDMR Shareholding
25th Jul 20227:00 amRNSTrading Update
20th Jun 20222:31 pmRNSResults of AGM
10th Jun 202212:21 pmRNSDirector/PDMR Shareholding
9th Jun 20225:53 pmRNSAnnual Report & Notice of AGM - Correction
7th Jun 20227:00 amRNSAnnual Report & Notice of AGM
30th May 20224:22 pmRNSDirector/PDMR Shareholding
30th May 20227:00 amRNSDirectorate Changes
23rd May 20224:27 pmRNSHolding(s) in Company
20th May 20227:00 amRNSInvestor Presentation
17th May 20227:00 amRNSDirectorate Changes
17th May 20227:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.